Dianthus Therapeutics appoints Steven Romano, M.D. to Board of Directors

Dianthus Therapeutics, Inc. /DE/

Appointed Steven Romano, M.D. as Class III director and member of Science & Technology Committee, effective September 16, 2024.
Initial option grant of 22,000 shares vesting one-third annually over three years.
Annual cash compensation: $40,000 for board service plus $5,000 for S&T Committee, paid quarterly.
Dr. Romano will also be eligible for future annual equity grants under the Non-Employee Director Compensation Policy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steven Romano, M.D.

Class III director

DNTH · Dianthus Therapeutics, Inc. /DE/

Effective: 2024-09-16
Filed: September 16, 2024, 7:59 PM ET

On September 16, 2024, the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”) appointed Steven Romano, M.D. as a Class III director of the Company and as a member of the Science and Technology Committee of the Board (the “S&T Committee”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Romano, M.D. was appointed as Class III director at Dianthus Therapeutics, Inc. /DE/.

Action: appointed
Role: Class III director

Exact text from the filing

On September 16, 2024, the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”) appointed Steven Romano, M.D. as a Class III director of the Company and as a member of the Science and Technology Committee of the Board (the “S&T Committee”), effective immediately.

View on SEC.gov

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-24-106820

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.